nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—Nilotinib—hematologic cancer	0.301	1	CrCtD
Imatinib—Ponatinib—Nilotinib—hematologic cancer	0.171	1	CrCrCtD
Imatinib—ABL2—hematologic cancer	0.0367	0.188	CbGaD
Imatinib—LCK—hematologic cancer	0.035	0.179	CbGaD
Imatinib—CSF1R—hematologic cancer	0.0211	0.108	CbGaD
Imatinib—PDGFRB—hematologic cancer	0.0184	0.0942	CbGaD
Imatinib—PDGFRA—hematologic cancer	0.0179	0.0918	CbGaD
Imatinib—ABL1—hematologic cancer	0.0164	0.084	CbGaD
Imatinib—KIT—hematologic cancer	0.0132	0.0674	CbGaD
Imatinib—CA9—hematologic cancer	0.0126	0.0647	CbGaD
Imatinib—SLC22A1—hematologic cancer	0.0104	0.0534	CbGaD
Imatinib—CA3—Nilotinib—hematologic cancer	0.0101	0.0509	CbGbCtD
Imatinib—ABCG2—hematologic cancer	0.00729	0.0373	CbGaD
Imatinib—CSF1R—Nilotinib—hematologic cancer	0.00691	0.035	CbGbCtD
Imatinib—PDGFRA—Nilotinib—hematologic cancer	0.00691	0.035	CbGbCtD
Imatinib—KIT—Nilotinib—hematologic cancer	0.00691	0.035	CbGbCtD
Imatinib—ABL2—Nilotinib—hematologic cancer	0.00691	0.035	CbGbCtD
Imatinib—PDGFRB—Nilotinib—hematologic cancer	0.00629	0.0318	CbGbCtD
Imatinib—LCK—Nilotinib—hematologic cancer	0.00629	0.0318	CbGbCtD
Imatinib—CSF1R—Dasatinib—hematologic cancer	0.00611	0.0309	CbGbCtD
Imatinib—PDGFRA—Dasatinib—hematologic cancer	0.00611	0.0309	CbGbCtD
Imatinib—ABL2—Dasatinib—hematologic cancer	0.00611	0.0309	CbGbCtD
Imatinib—KIT—Dasatinib—hematologic cancer	0.00611	0.0309	CbGbCtD
Imatinib—PDGFRB—Dasatinib—hematologic cancer	0.00556	0.0281	CbGbCtD
Imatinib—LCK—Dasatinib—hematologic cancer	0.00556	0.0281	CbGbCtD
Imatinib—ABL1—Nilotinib—hematologic cancer	0.00499	0.0253	CbGbCtD
Imatinib—ABL1—Dasatinib—hematologic cancer	0.00441	0.0224	CbGbCtD
Imatinib—SLC47A1—Mitoxantrone—hematologic cancer	0.00436	0.0221	CbGbCtD
Imatinib—CA14—Nilotinib—hematologic cancer	0.00418	0.0212	CbGbCtD
Imatinib—CA6—Nilotinib—hematologic cancer	0.00397	0.0201	CbGbCtD
Imatinib—CA7—Nilotinib—hematologic cancer	0.00346	0.0175	CbGbCtD
Imatinib—ALB—hematologic cancer	0.00318	0.0163	CbGaD
Imatinib—ABCB1—hematologic cancer	0.00303	0.0155	CbGaD
Imatinib—CA12—Nilotinib—hematologic cancer	0.00297	0.015	CbGbCtD
Imatinib—CA9—Nilotinib—hematologic cancer	0.00297	0.015	CbGbCtD
Imatinib—ABCG2—Clofarabine—hematologic cancer	0.0028	0.0142	CbGbCtD
Imatinib—CA1—Nilotinib—hematologic cancer	0.00278	0.0141	CbGbCtD
Imatinib—CA2—Nilotinib—hematologic cancer	0.0024	0.0122	CbGbCtD
Imatinib—SLC22A2—Daunorubicin—hematologic cancer	0.00222	0.0112	CbGbCtD
Imatinib—SLC22A2—Cytarabine—hematologic cancer	0.00196	0.00992	CbGbCtD
Imatinib—SLC22A2—Cladribine—hematologic cancer	0.00185	0.00936	CbGbCtD
Imatinib—SLC22A1—Cytarabine—hematologic cancer	0.0017	0.00861	CbGbCtD
Imatinib—CYP1A2—Anagrelide—hematologic cancer	0.00166	0.00842	CbGbCtD
Imatinib—ABCG2—Daunorubicin—hematologic cancer	0.00164	0.0083	CbGbCtD
Imatinib—SLC22A1—Cladribine—hematologic cancer	0.00161	0.00813	CbGbCtD
Imatinib—PTGS1—Bortezomib—hematologic cancer	0.00158	0.00801	CbGbCtD
Imatinib—ABCG2—Teniposide—hematologic cancer	0.00142	0.00721	CbGbCtD
Imatinib—PTGS1—Thalidomide—hematologic cancer	0.00138	0.00698	CbGbCtD
Imatinib—ABCG2—Cladribine—hematologic cancer	0.00137	0.00691	CbGbCtD
Imatinib—PTGS1—Ifosfamide—hematologic cancer	0.00121	0.00614	CbGbCtD
Imatinib—ABCG2—Nilotinib—hematologic cancer	0.00114	0.00578	CbGbCtD
Imatinib—CYP2C9—Bexarotene—hematologic cancer	0.00104	0.00526	CbGbCtD
Imatinib—ABCG2—Dasatinib—hematologic cancer	0.00101	0.0051	CbGbCtD
Imatinib—ABCB1—Lenalidomide—hematologic cancer	0.00101	0.0051	CbGbCtD
Imatinib—ABCG2—Mitoxantrone—hematologic cancer	0.000996	0.00504	CbGbCtD
Imatinib—CYP3A7—Ifosfamide—hematologic cancer	0.000971	0.00491	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Ifosfamide—hematologic cancer	0.000971	0.00491	CbGbCtD
Imatinib—SLC22A2—Vinblastine—hematologic cancer	0.000944	0.00478	CbGbCtD
Imatinib—CYP3A5—Daunorubicin—hematologic cancer	0.000908	0.0046	CbGbCtD
Imatinib—CYP2D6—Lomustine—hematologic cancer	0.000883	0.00447	CbGbCtD
Imatinib—CYP1A2—Carmustine—hematologic cancer	0.000874	0.00442	CbGbCtD
Imatinib—SLC22A2—Cisplatin—hematologic cancer	0.000866	0.00438	CbGbCtD
Imatinib—CYP2C9—Idarubicin—hematologic cancer	0.000861	0.00436	CbGbCtD
Imatinib—CYP3A5—Thalidomide—hematologic cancer	0.000827	0.00419	CbGbCtD
Imatinib—CYP3A5—Teniposide—hematologic cancer	0.000789	0.00399	CbGbCtD
Imatinib—CYP2D6—Idarubicin—hematologic cancer	0.000787	0.00398	CbGbCtD
Imatinib—ABCG2—Irinotecan—hematologic cancer	0.000784	0.00397	CbGbCtD
Imatinib—CYP2C19—Bortezomib—hematologic cancer	0.000766	0.00388	CbGbCtD
Imatinib—CYP1A2—Methoxsalen—hematologic cancer	0.000743	0.00376	CbGbCtD
Imatinib—CYP3A5—Ifosfamide—hematologic cancer	0.000728	0.00369	CbGbCtD
Imatinib—CYP1A2—Bortezomib—hematologic cancer	0.000707	0.00358	CbGbCtD
Imatinib—ABCG2—Vincristine—hematologic cancer	0.000685	0.00347	CbGbCtD
Imatinib—CYP1A2—Daunorubicin—hematologic cancer	0.000676	0.00342	CbGbCtD
Imatinib—CYP2D6—Hydroxyurea—hematologic cancer	0.000669	0.00339	CbGbCtD
Imatinib—CYP2C19—Thalidomide—hematologic cancer	0.000667	0.00338	CbGbCtD
Imatinib—CYP1A2—Alitretinoin—hematologic cancer	0.000662	0.00335	CbGbCtD
Imatinib—ABCG2—Cisplatin—hematologic cancer	0.000639	0.00324	CbGbCtD
Imatinib—CYP2C9—Bortezomib—hematologic cancer	0.000637	0.00322	CbGbCtD
Imatinib—CYP2C19—Teniposide—hematologic cancer	0.000636	0.00322	CbGbCtD
Imatinib—ABCG2—Etoposide—hematologic cancer	0.000628	0.00318	CbGbCtD
Imatinib—CYP1A2—Thalidomide—hematologic cancer	0.000615	0.00312	CbGbCtD
Imatinib—CYP3A4—Bexarotene—hematologic cancer	0.000604	0.00306	CbGbCtD
Imatinib—ABCB1—Daunorubicin—hematologic cancer	0.000591	0.00299	CbGbCtD
Imatinib—CYP2C19—Ifosfamide—hematologic cancer	0.000587	0.00297	CbGbCtD
Imatinib—CYP2D6—Bortezomib—hematologic cancer	0.000582	0.00295	CbGbCtD
Imatinib—PTGS1—Etoposide—hematologic cancer	0.00058	0.00294	CbGbCtD
Imatinib—CYP3A7—Irinotecan—hematologic cancer	0.000579	0.00293	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Irinotecan—hematologic cancer	0.000579	0.00293	CbGbCtD
Imatinib—ABCB1—Alitretinoin—hematologic cancer	0.000579	0.00293	CbGbCtD
Imatinib—ALB—Prednisone—hematologic cancer	0.00057	0.00289	CbGbCtD
Imatinib—CYP3A4—Lomustine—hematologic cancer	0.000561	0.00284	CbGbCtD
Imatinib—CYP3A4—Busulfan—hematologic cancer	0.000561	0.00284	CbGbCtD
Imatinib—CYP3A5—Dasatinib—hematologic cancer	0.000559	0.00283	CbGbCtD
Imatinib—CYP2C9—Thalidomide—hematologic cancer	0.000555	0.00281	CbGbCtD
Imatinib—ALB—Irinotecan—hematologic cancer	0.00054	0.00274	CbGbCtD
Imatinib—CYP1A2—Dacarbazine—hematologic cancer	0.000529	0.00268	CbGbCtD
Imatinib—CYP2C9—Teniposide—hematologic cancer	0.000529	0.00268	CbGbCtD
Imatinib—ABCG2—Dexamethasone—hematologic cancer	0.000516	0.00261	CbGbCtD
Imatinib—CYP3A7—Vincristine—hematologic cancer	0.000506	0.00256	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Vincristine—hematologic cancer	0.000506	0.00256	CbGbCtD
Imatinib—CYP3A4—Thiotepa—hematologic cancer	0.0005	0.00253	CbGbCtD
Imatinib—CYP2C9—Ifosfamide—hematologic cancer	0.000488	0.00247	CbGbCtD
Imatinib—HIPK4—gonad—hematologic cancer	0.000457	0.0261	CbGeAlD
Imatinib—CYP3A5—Irinotecan—hematologic cancer	0.000434	0.0022	CbGbCtD
Imatinib—ABCG2—Doxorubicin—hematologic cancer	0.000428	0.00217	CbGbCtD
Imatinib—CYP2C9—Nilotinib—hematologic cancer	0.000424	0.00215	CbGbCtD
Imatinib—CYP1A2—Dasatinib—hematologic cancer	0.000416	0.00211	CbGbCtD
Imatinib—ABCG2—Methotrexate—hematologic cancer	0.000415	0.0021	CbGbCtD
Imatinib—NTRK1—testis—hematologic cancer	0.000412	0.0236	CbGeAlD
Imatinib—ABCB1—Nilotinib—hematologic cancer	0.000411	0.00208	CbGbCtD
Imatinib—ABCB1—Vinorelbine—hematologic cancer	0.000408	0.00207	CbGbCtD
Imatinib—ABCA3—blood—hematologic cancer	0.000394	0.0225	CbGeAlD
Imatinib—CYP3A4—Methoxsalen—hematologic cancer	0.000389	0.00197	CbGbCtD
Imatinib—CYP2D6—Nilotinib—hematologic cancer	0.000388	0.00196	CbGbCtD
Imatinib—CYP2D6—Vinorelbine—hematologic cancer	0.000384	0.00195	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Dexamethasone—hematologic cancer	0.000381	0.00193	CbGbCtD
Imatinib—CYP3A7—Dexamethasone—hematologic cancer	0.000381	0.00193	CbGbCtD
Imatinib—CYP3A5—Vincristine—hematologic cancer	0.00038	0.00192	CbGbCtD
Imatinib—CYP3A4—Bortezomib—hematologic cancer	0.00037	0.00187	CbGbCtD
Imatinib—CYP2C19—Prednisone—hematologic cancer	0.00037	0.00187	CbGbCtD
Imatinib—ABCB1—Dasatinib—hematologic cancer	0.000364	0.00184	CbGbCtD
Imatinib—DDR1—blood—hematologic cancer	0.000363	0.0208	CbGeAlD
Imatinib—ABCB1—Mitoxantrone—hematologic cancer	0.000359	0.00182	CbGbCtD
Imatinib—CYP3A4—Daunorubicin—hematologic cancer	0.000354	0.00179	CbGbCtD
Imatinib—CYP3A5—Etoposide—hematologic cancer	0.000348	0.00176	CbGbCtD
Imatinib—ABCA3—lung—hematologic cancer	0.000345	0.0197	CbGeAlD
Imatinib—HIPK4—testis—hematologic cancer	0.000329	0.0188	CbGeAlD
Imatinib—ABCA3—testis—hematologic cancer	0.000326	0.0186	CbGeAlD
Imatinib—ABCB1—Betamethasone—hematologic cancer	0.00032	0.00162	CbGbCtD
Imatinib—DDR1—lung—hematologic cancer	0.000318	0.0182	CbGeAlD
Imatinib—ABCB1—Gemcitabine—hematologic cancer	0.000317	0.00161	CbGbCtD
Imatinib—ABCB1—Prednisolone—hematologic cancer	0.000316	0.0016	CbGbCtD
Imatinib—CYP3A4—Cytarabine—hematologic cancer	0.000312	0.00158	CbGbCtD
Imatinib—CYP3A4—Teniposide—hematologic cancer	0.000308	0.00156	CbGbCtD
Imatinib—DDR1—testis—hematologic cancer	0.0003	0.0172	CbGeAlD
Imatinib—ABCB1—Prednisone—hematologic cancer	0.000298	0.00151	CbGbCtD
Imatinib—CYP3A5—Dexamethasone—hematologic cancer	0.000286	0.00145	CbGbCtD
Imatinib—ALB—Methotrexate—hematologic cancer	0.000286	0.00145	CbGbCtD
Imatinib—CYP3A4—Ifosfamide—hematologic cancer	0.000284	0.00144	CbGbCtD
Imatinib—ABCB1—Irinotecan—hematologic cancer	0.000283	0.00143	CbGbCtD
Imatinib—Ponatinib—BCR—hematologic cancer	0.000259	0.129	CrCbGaD
Imatinib—CYP1A2—Etoposide—hematologic cancer	0.000259	0.00131	CbGbCtD
Imatinib—PIP4K2C—gonad—hematologic cancer	0.000257	0.0147	CbGeAlD
Imatinib—CYP3A4—Ruxolitinib—hematologic cancer	0.000255	0.00129	CbGbCtD
Imatinib—ABCB1—Vinblastine—hematologic cancer	0.000251	0.00127	CbGbCtD
Imatinib—PDGFRA—hematopoietic system—hematologic cancer	0.000248	0.0142	CbGeAlD
Imatinib—ABCB1—Vincristine—hematologic cancer	0.000247	0.00125	CbGbCtD
Imatinib—CYP3A4—Nilotinib—hematologic cancer	0.000246	0.00125	CbGbCtD
Imatinib—CYP3A4—Vinorelbine—hematologic cancer	0.000244	0.00124	CbGbCtD
Imatinib—CYP2C9—Cisplatin—hematologic cancer	0.000237	0.0012	CbGbCtD
Imatinib—ABL2—blood—hematologic cancer	0.000237	0.0136	CbGeAlD
Imatinib—CYP2D6—Vinblastine—hematologic cancer	0.000237	0.0012	CbGbCtD
Imatinib—ABCA3—lymph node—hematologic cancer	0.000236	0.0135	CbGeAlD
Imatinib—CYP2C19—Dexamethasone—hematologic cancer	0.000231	0.00117	CbGbCtD
Imatinib—ABCB1—Cisplatin—hematologic cancer	0.00023	0.00117	CbGbCtD
Imatinib—ABCB1—Etoposide—hematologic cancer	0.000226	0.00115	CbGbCtD
Imatinib—PIP4K2C—blood—hematologic cancer	0.000224	0.0128	CbGeAlD
Imatinib—CYP3A4—Triamcinolone—hematologic cancer	0.000224	0.00113	CbGbCtD
Imatinib—CSF1R—hematopoietic system—hematologic cancer	0.000218	0.0125	CbGeAlD
Imatinib—CYP3A4—Dasatinib—hematologic cancer	0.000218	0.0011	CbGbCtD
Imatinib—DDR1—lymph node—hematologic cancer	0.000218	0.0125	CbGeAlD
Imatinib—PIP4K2C—bone marrow—hematologic cancer	0.000217	0.0124	CbGeAlD
Imatinib—CYP3A4—Mitoxantrone—hematologic cancer	0.000215	0.00109	CbGbCtD
Imatinib—ABL2—lung—hematologic cancer	0.000208	0.0119	CbGeAlD
Imatinib—CA3—bone marrow—hematologic cancer	0.000207	0.0118	CbGeAlD
Imatinib—SLC47A1—hematopoietic system—hematologic cancer	0.000199	0.0114	CbGeAlD
Imatinib—LCK—blood—hematologic cancer	0.000199	0.0114	CbGeAlD
Imatinib—KIT—hematopoietic system—hematologic cancer	0.000198	0.0113	CbGeAlD
Imatinib—PIP4K2C—lung—hematologic cancer	0.000197	0.0112	CbGeAlD
Imatinib—ABL2—testis—hematologic cancer	0.000196	0.0112	CbGeAlD
Imatinib—PDGFRB—hematopoietic system—hematologic cancer	0.000194	0.0111	CbGeAlD
Imatinib—LCK—bone marrow—hematologic cancer	0.000193	0.011	CbGeAlD
Imatinib—CYP2C9—Dexamethasone—hematologic cancer	0.000192	0.000971	CbGbCtD
Imatinib—CYP3A4—Betamethasone—hematologic cancer	0.000192	0.000971	CbGbCtD
Imatinib—CYP3A4—Prednisolone—hematologic cancer	0.000189	0.000958	CbGbCtD
Imatinib—PDGFRA—gonad—hematologic cancer	0.000189	0.0108	CbGeAlD
Imatinib—CA3—lung—hematologic cancer	0.000188	0.0107	CbGeAlD
Imatinib—ABCB1—Dexamethasone—hematologic cancer	0.000186	0.000943	CbGbCtD
Imatinib—PIP4K2C—testis—hematologic cancer	0.000185	0.0106	CbGeAlD
Imatinib—ORM1—hematopoietic system—hematologic cancer	0.000182	0.0104	CbGeAlD
Imatinib—CA1—hematopoietic system—hematologic cancer	0.000181	0.0104	CbGeAlD
Imatinib—CYP3A4—Prednisone—hematologic cancer	0.000179	0.000905	CbGbCtD
Imatinib—CA3—testis—hematologic cancer	0.000177	0.0101	CbGeAlD
Imatinib—CYP2D6—Dexamethasone—hematologic cancer	0.000175	0.000888	CbGbCtD
Imatinib—LCK—lung—hematologic cancer	0.000174	0.00998	CbGeAlD
Imatinib—ABL1—hematopoietic system—hematologic cancer	0.000173	0.00987	CbGeAlD
Imatinib—CA9—testis—hematologic cancer	0.00017	0.0097	CbGeAlD
Imatinib—CYP3A4—Irinotecan—hematologic cancer	0.000169	0.000858	CbGbCtD
Imatinib—Ponatinib—FLT3—hematologic cancer	0.000167	0.0833	CrCbGaD
Imatinib—CSF1R—gonad—hematologic cancer	0.000166	0.00949	CbGeAlD
Imatinib—NQO2—blood—hematologic cancer	0.000165	0.00942	CbGeAlD
Imatinib—LCK—testis—hematologic cancer	0.000165	0.00942	CbGeAlD
Imatinib—PDGFRA—blood—hematologic cancer	0.000164	0.00939	CbGeAlD
Imatinib—NQO2—bone marrow—hematologic cancer	0.000159	0.00911	CbGeAlD
Imatinib—ABCB1—Doxorubicin—hematologic cancer	0.000154	0.000782	CbGbCtD
Imatinib—SLC47A1—gonad—hematologic cancer	0.000152	0.00867	CbGeAlD
Imatinib—KIT—gonad—hematologic cancer	0.000151	0.00862	CbGeAlD
Imatinib—CYP3A4—Vinblastine—hematologic cancer	0.000151	0.000763	CbGbCtD
Imatinib—ABCB1—Methotrexate—hematologic cancer	0.00015	0.000758	CbGbCtD
Imatinib—CYP3A4—Vincristine—hematologic cancer	0.000148	0.00075	CbGbCtD
Imatinib—PDGFRB—gonad—hematologic cancer	0.000147	0.00842	CbGeAlD
Imatinib—CYP2D6—Doxorubicin—hematologic cancer	0.000146	0.000737	CbGbCtD
Imatinib—CSF1R—blood—hematologic cancer	0.000145	0.00827	CbGeAlD
Imatinib—NQO2—lung—hematologic cancer	0.000144	0.00826	CbGeAlD
Imatinib—PDGFRA—lung—hematologic cancer	0.000144	0.00824	CbGeAlD
Imatinib—ABL2—lymph node—hematologic cancer	0.000142	0.00813	CbGeAlD
Imatinib—Ponatinib—LCK—hematologic cancer	0.000142	0.0708	CrCbGaD
Imatinib—CSF1R—bone marrow—hematologic cancer	0.00014	0.008	CbGeAlD
Imatinib—NQO2—testis—hematologic cancer	0.000136	0.00779	CbGeAlD
Imatinib—PDGFRA—testis—hematologic cancer	0.000136	0.00777	CbGeAlD
Imatinib—CYP3A4—Etoposide—hematologic cancer	0.000136	0.000687	CbGbCtD
Imatinib—PIP4K2C—lymph node—hematologic cancer	0.000134	0.00769	CbGeAlD
Imatinib—CA12—lung—hematologic cancer	0.000133	0.0076	CbGeAlD
Imatinib—SLC47A1—blood—hematologic cancer	0.000132	0.00755	CbGeAlD
Imatinib—KIT—blood—hematologic cancer	0.000131	0.00751	CbGeAlD
Imatinib—ABL1—gonad—hematologic cancer	0.000131	0.0075	CbGeAlD
Imatinib—ABL1—Topotecan—Irinotecan—hematologic cancer	0.00013	0.169	CbGdCrCtD
Imatinib—CA3—lymph node—hematologic cancer	0.000128	0.00734	CbGeAlD
Imatinib—PDGFRB—blood—hematologic cancer	0.000128	0.00733	CbGeAlD
Imatinib—CYP2C19—hematopoietic system—hematologic cancer	0.000128	0.00733	CbGeAlD
Imatinib—KIT—bone marrow—hematologic cancer	0.000127	0.00727	CbGeAlD
Imatinib—CSF1R—lung—hematologic cancer	0.000127	0.00725	CbGeAlD
Imatinib—PDGFRB—bone marrow—hematologic cancer	0.000124	0.0071	CbGeAlD
Imatinib—ORM1—blood—hematologic cancer	0.00012	0.00688	CbGeAlD
Imatinib—CA1—blood—hematologic cancer	0.00012	0.00687	CbGeAlD
Imatinib—CSF1R—testis—hematologic cancer	0.00012	0.00684	CbGeAlD
Imatinib—LCK—lymph node—hematologic cancer	0.000119	0.00682	CbGeAlD
Imatinib—Ponatinib—FGFR3—hematologic cancer	0.000119	0.0594	CrCbGaD
Imatinib—CA2—hematopoietic system—hematologic cancer	0.000117	0.00672	CbGeAlD
Imatinib—ORM1—bone marrow—hematologic cancer	0.000116	0.00666	CbGeAlD
Imatinib—CA1—bone marrow—hematologic cancer	0.000116	0.00665	CbGeAlD
Imatinib—SLC47A1—lung—hematologic cancer	0.000116	0.00662	CbGeAlD
Imatinib—KIT—lung—hematologic cancer	0.000115	0.00658	CbGeAlD
Imatinib—ABL1—blood—hematologic cancer	0.000114	0.00654	CbGeAlD
Imatinib—PDGFRB—lung—hematologic cancer	0.000112	0.00643	CbGeAlD
Imatinib—CYP3A4—Dexamethasone—hematologic cancer	0.000112	0.000565	CbGbCtD
Imatinib—ABL1—bone marrow—hematologic cancer	0.000111	0.00633	CbGeAlD
Imatinib—SLC22A1—blood—hematologic cancer	0.00011	0.0063	CbGeAlD
Imatinib—Nilotinib—ABL2—hematologic cancer	0.00011	0.0548	CrCbGaD
Imatinib—SLC47A1—testis—hematologic cancer	0.000109	0.00625	CbGeAlD
Imatinib—KIT—testis—hematologic cancer	0.000109	0.00621	CbGeAlD
Imatinib—Ponatinib—RET—hematologic cancer	0.000108	0.0537	CrCbGaD
Imatinib—PDGFRB—testis—hematologic cancer	0.000106	0.00607	CbGeAlD
Imatinib—ORM1—lung—hematologic cancer	0.000105	0.00603	CbGeAlD
Imatinib—CA1—lung—hematologic cancer	0.000105	0.00602	CbGeAlD
Imatinib—Nilotinib—LCK—hematologic cancer	0.000105	0.0523	CrCbGaD
Imatinib—CYP1A2—hematopoietic system—hematologic cancer	0.000105	0.00599	CbGeAlD
Imatinib—CYP3A5—hematopoietic system—hematologic cancer	0.000101	0.00578	CbGeAlD
Imatinib—ABL1—lung—hematologic cancer	0.0001	0.00573	CbGeAlD
Imatinib—CYP2C9—hematopoietic system—hematologic cancer	9.94e-05	0.00568	CbGeAlD
Imatinib—NQO2—lymph node—hematologic cancer	9.87e-05	0.00565	CbGeAlD
Imatinib—PDGFRA—lymph node—hematologic cancer	9.85e-05	0.00563	CbGeAlD
Imatinib—Nilotinib—MAPK8—hematologic cancer	9.67e-05	0.0483	CrCbGaD
Imatinib—ABL1—testis—hematologic cancer	9.46e-05	0.00541	CbGeAlD
Imatinib—Nilotinib—MAPK14—hematologic cancer	9.34e-05	0.0466	CrCbGaD
Imatinib—Nilotinib—FGR—hematologic cancer	9.34e-05	0.0466	CrCbGaD
Imatinib—CYP3A4—Doxorubicin—hematologic cancer	9.25e-05	0.000469	CbGbCtD
Imatinib—PTGS1—hematopoietic system—hematologic cancer	9.08e-05	0.00519	CbGeAlD
Imatinib—ABL1—Idarubicin—Daunorubicin—hematologic cancer	8.76e-05	0.114	CbGdCrCtD
Imatinib—ABL1—Epirubicin—Daunorubicin—hematologic cancer	8.76e-05	0.114	CbGdCrCtD
Imatinib—ABL1—Doxorubicin—Daunorubicin—hematologic cancer	8.76e-05	0.114	CbGdCrCtD
Imatinib—ALB—testis—hematologic cancer	8.73e-05	0.00499	CbGeAlD
Imatinib—CSF1R—lymph node—hematologic cancer	8.67e-05	0.00496	CbGeAlD
Imatinib—CYP2C19—blood—hematologic cancer	8.49e-05	0.00486	CbGeAlD
Imatinib—SLC47A1—lymph node—hematologic cancer	7.92e-05	0.00453	CbGeAlD
Imatinib—KIT—lymph node—hematologic cancer	7.87e-05	0.0045	CbGeAlD
Imatinib—CA2—blood—hematologic cancer	7.78e-05	0.00445	CbGeAlD
Imatinib—PDGFRB—lymph node—hematologic cancer	7.69e-05	0.0044	CbGeAlD
Imatinib—CYP3A4—hematopoietic system—hematologic cancer	7.58e-05	0.00433	CbGeAlD
Imatinib—CA2—bone marrow—hematologic cancer	7.53e-05	0.00431	CbGeAlD
Imatinib—CYP2D6—hematopoietic system—hematologic cancer	7.46e-05	0.00427	CbGeAlD
Imatinib—Ponatinib—PDGFRA—hematologic cancer	7.26e-05	0.0363	CrCbGaD
Imatinib—ORM1—lymph node—hematologic cancer	7.21e-05	0.00413	CbGeAlD
Imatinib—ABCG2—blood—hematologic cancer	7.21e-05	0.00412	CbGeAlD
Imatinib—CA1—lymph node—hematologic cancer	7.2e-05	0.00412	CbGeAlD
Imatinib—ABCG2—bone marrow—hematologic cancer	6.98e-05	0.00399	CbGeAlD
Imatinib—CYP1A2—blood—hematologic cancer	6.94e-05	0.00397	CbGeAlD
Imatinib—ABL1—lymph node—hematologic cancer	6.85e-05	0.00392	CbGeAlD
Imatinib—CA2—lung—hematologic cancer	6.82e-05	0.0039	CbGeAlD
Imatinib—CYP3A5—blood—hematologic cancer	6.69e-05	0.00383	CbGeAlD
Imatinib—Ponatinib—ABL1—hematologic cancer	6.64e-05	0.0332	CrCbGaD
Imatinib—ABL1—Epirubicin—Idarubicin—hematologic cancer	6.64e-05	0.0865	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Idarubicin—hematologic cancer	6.64e-05	0.0865	CbGdCrCtD
Imatinib—ABL1—Doxorubicin—Idarubicin—hematologic cancer	6.64e-05	0.0865	CbGdCrCtD
Imatinib—CYP2C9—blood—hematologic cancer	6.59e-05	0.00377	CbGeAlD
Imatinib—CA2—testis—hematologic cancer	6.44e-05	0.00368	CbGeAlD
Imatinib—ALB—lymph node—hematologic cancer	6.33e-05	0.00362	CbGeAlD
Imatinib—ABCG2—lung—hematologic cancer	6.32e-05	0.00361	CbGeAlD
Imatinib—Nilotinib—CSF1R—hematologic cancer	6.31e-05	0.0315	CrCbGaD
Imatinib—CYP1A2—lung—hematologic cancer	6.08e-05	0.00348	CbGeAlD
Imatinib—Ponatinib—SRC—hematologic cancer	6.01e-05	0.03	CrCbGaD
Imatinib—PTGS1—blood—hematologic cancer	6.01e-05	0.00344	CbGeAlD
Imatinib—ABCG2—testis—hematologic cancer	5.96e-05	0.00341	CbGeAlD
Imatinib—CYP3A5—lung—hematologic cancer	5.87e-05	0.00335	CbGeAlD
Imatinib—Nilotinib—PDGFRB—hematologic cancer	5.5e-05	0.0275	CrCbGaD
Imatinib—ABCB1—hematopoietic system—hematologic cancer	5.37e-05	0.00307	CbGeAlD
Imatinib—Nilotinib—PDGFRA—hematologic cancer	5.36e-05	0.0268	CrCbGaD
Imatinib—Ponatinib—KIT—hematologic cancer	5.33e-05	0.0266	CrCbGaD
Imatinib—PTGS1—lung—hematologic cancer	5.27e-05	0.00301	CbGeAlD
Imatinib—CYP3A4—blood—hematologic cancer	5.02e-05	0.00287	CbGeAlD
Imatinib—PTGS1—testis—hematologic cancer	4.97e-05	0.00284	CbGeAlD
Imatinib—CYP2D6—blood—hematologic cancer	4.94e-05	0.00283	CbGeAlD
Imatinib—Nilotinib—ABL1—hematologic cancer	4.9e-05	0.0245	CrCbGaD
Imatinib—Nilotinib—BRAF—hematologic cancer	4.9e-05	0.0245	CrCbGaD
Imatinib—CA2—lymph node—hematologic cancer	4.67e-05	0.00267	CbGeAlD
Imatinib—ABCG2—lymph node—hematologic cancer	4.32e-05	0.00247	CbGeAlD
Imatinib—CYP2D6—testis—hematologic cancer	4.09e-05	0.00234	CbGeAlD
Imatinib—ABCB1—gonad—hematologic cancer	4.08e-05	0.00233	CbGeAlD
Imatinib—Nilotinib—KIT—hematologic cancer	3.94e-05	0.0196	CrCbGaD
Imatinib—Nilotinib—UGT1A1—hematologic cancer	3.88e-05	0.0194	CrCbGaD
Imatinib—Nilotinib—CA9—hematologic cancer	3.78e-05	0.0189	CrCbGaD
Imatinib—PTGS1—lymph node—hematologic cancer	3.6e-05	0.00206	CbGeAlD
Imatinib—ABCB1—blood—hematologic cancer	3.55e-05	0.00203	CbGeAlD
Imatinib—ABCB1—bone marrow—hematologic cancer	3.44e-05	0.00197	CbGeAlD
Imatinib—ABCB1—lung—hematologic cancer	3.12e-05	0.00178	CbGeAlD
Imatinib—ABL1—Idarubicin—Epirubicin—hematologic cancer	3.05e-05	0.0397	CbGdCrCtD
Imatinib—ABL1—Doxorubicin—Epirubicin—hematologic cancer	3.05e-05	0.0397	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Epirubicin—hematologic cancer	3.05e-05	0.0397	CbGdCrCtD
Imatinib—Ponatinib—ABCG2—hematologic cancer	2.95e-05	0.0147	CrCbGaD
Imatinib—ABCB1—testis—hematologic cancer	2.94e-05	0.00168	CbGeAlD
Imatinib—ABL1—Epirubicin—Doxorubicin—hematologic cancer	2.82e-05	0.0367	CbGdCrCtD
Imatinib—ABL1—Idarubicin—Doxorubicin—hematologic cancer	2.82e-05	0.0367	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Doxorubicin—hematologic cancer	2.82e-05	0.0367	CbGdCrCtD
Imatinib—Nilotinib—ABCG2—hematologic cancer	2.18e-05	0.0109	CrCbGaD
Imatinib—ABCB1—lymph node—hematologic cancer	2.13e-05	0.00122	CbGeAlD
Imatinib—Ponatinib—ABCB1—hematologic cancer	1.23e-05	0.00613	CrCbGaD
Imatinib—Nilotinib—ABCB1—hematologic cancer	9.07e-06	0.00453	CrCbGaD
Imatinib—Tinnitus—Doxorubicin—hematologic cancer	2.6e-06	3.72e-05	CcSEcCtD
Imatinib—Anaemia—Methotrexate—hematologic cancer	2.59e-06	3.71e-05	CcSEcCtD
Imatinib—Feeling abnormal—Dexamethasone—hematologic cancer	2.59e-06	3.71e-05	CcSEcCtD
Imatinib—Feeling abnormal—Betamethasone—hematologic cancer	2.59e-06	3.71e-05	CcSEcCtD
Imatinib—Cardiac disorder—Doxorubicin—hematologic cancer	2.59e-06	3.7e-05	CcSEcCtD
Imatinib—Flushing—Doxorubicin—hematologic cancer	2.59e-06	3.7e-05	CcSEcCtD
Imatinib—Flatulence—Epirubicin—hematologic cancer	2.58e-06	3.7e-05	CcSEcCtD
Imatinib—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.57e-06	3.68e-05	CcSEcCtD
Imatinib—Gastrointestinal pain—Betamethasone—hematologic cancer	2.57e-06	3.68e-05	CcSEcCtD
Imatinib—Dysgeusia—Epirubicin—hematologic cancer	2.57e-06	3.68e-05	CcSEcCtD
Imatinib—Hypersensitivity—Triamcinolone—hematologic cancer	2.55e-06	3.65e-05	CcSEcCtD
Imatinib—Back pain—Epirubicin—hematologic cancer	2.54e-06	3.63e-05	CcSEcCtD
Imatinib—Angiopathy—Doxorubicin—hematologic cancer	2.53e-06	3.62e-05	CcSEcCtD
Imatinib—Malaise—Methotrexate—hematologic cancer	2.53e-06	3.62e-05	CcSEcCtD
Imatinib—Dizziness—Etoposide—hematologic cancer	2.52e-06	3.61e-05	CcSEcCtD
Imatinib—Muscle spasms—Epirubicin—hematologic cancer	2.52e-06	3.61e-05	CcSEcCtD
Imatinib—Immune system disorder—Doxorubicin—hematologic cancer	2.52e-06	3.6e-05	CcSEcCtD
Imatinib—Vertigo—Methotrexate—hematologic cancer	2.52e-06	3.6e-05	CcSEcCtD
Imatinib—Mediastinal disorder—Doxorubicin—hematologic cancer	2.51e-06	3.6e-05	CcSEcCtD
Imatinib—Leukopenia—Methotrexate—hematologic cancer	2.51e-06	3.59e-05	CcSEcCtD
Imatinib—Chills—Doxorubicin—hematologic cancer	2.5e-06	3.58e-05	CcSEcCtD
Imatinib—Urticaria—Dexamethasone—hematologic cancer	2.49e-06	3.57e-05	CcSEcCtD
Imatinib—Urticaria—Betamethasone—hematologic cancer	2.49e-06	3.57e-05	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.49e-06	3.57e-05	CcSEcCtD
Imatinib—Dizziness—Prednisolone—hematologic cancer	2.49e-06	3.57e-05	CcSEcCtD
Imatinib—Arrhythmia—Doxorubicin—hematologic cancer	2.49e-06	3.57e-05	CcSEcCtD
Imatinib—Asthenia—Triamcinolone—hematologic cancer	2.48e-06	3.56e-05	CcSEcCtD
Imatinib—Abdominal pain—Dexamethasone—hematologic cancer	2.48e-06	3.56e-05	CcSEcCtD
Imatinib—Body temperature increased—Dexamethasone—hematologic cancer	2.48e-06	3.56e-05	CcSEcCtD
Imatinib—Body temperature increased—Betamethasone—hematologic cancer	2.48e-06	3.56e-05	CcSEcCtD
Imatinib—Abdominal pain—Betamethasone—hematologic cancer	2.48e-06	3.56e-05	CcSEcCtD
Imatinib—Nausea—Cisplatin—hematologic cancer	2.47e-06	3.54e-05	CcSEcCtD
Imatinib—Insomnia—Prednisone—hematologic cancer	2.47e-06	3.54e-05	CcSEcCtD
Imatinib—Vision blurred—Epirubicin—hematologic cancer	2.47e-06	3.54e-05	CcSEcCtD
Imatinib—Alopecia—Doxorubicin—hematologic cancer	2.46e-06	3.53e-05	CcSEcCtD
Imatinib—Paraesthesia—Prednisone—hematologic cancer	2.46e-06	3.52e-05	CcSEcCtD
Imatinib—Pruritus—Triamcinolone—hematologic cancer	2.45e-06	3.51e-05	CcSEcCtD
Imatinib—Cough—Methotrexate—hematologic cancer	2.44e-06	3.5e-05	CcSEcCtD
Imatinib—Mental disorder—Doxorubicin—hematologic cancer	2.44e-06	3.5e-05	CcSEcCtD
Imatinib—Ill-defined disorder—Epirubicin—hematologic cancer	2.43e-06	3.48e-05	CcSEcCtD
Imatinib—Convulsion—Methotrexate—hematologic cancer	2.43e-06	3.48e-05	CcSEcCtD
Imatinib—Vomiting—Etoposide—hematologic cancer	2.43e-06	3.48e-05	CcSEcCtD
Imatinib—Erythema—Doxorubicin—hematologic cancer	2.43e-06	3.47e-05	CcSEcCtD
Imatinib—Malnutrition—Doxorubicin—hematologic cancer	2.43e-06	3.47e-05	CcSEcCtD
Imatinib—Anaemia—Epirubicin—hematologic cancer	2.42e-06	3.47e-05	CcSEcCtD
Imatinib—Dyspepsia—Prednisone—hematologic cancer	2.41e-06	3.45e-05	CcSEcCtD
Imatinib—Rash—Etoposide—hematologic cancer	2.41e-06	3.45e-05	CcSEcCtD
Imatinib—Dermatitis—Etoposide—hematologic cancer	2.4e-06	3.44e-05	CcSEcCtD
Imatinib—Headache—Etoposide—hematologic cancer	2.39e-06	3.42e-05	CcSEcCtD
Imatinib—Flatulence—Doxorubicin—hematologic cancer	2.39e-06	3.42e-05	CcSEcCtD
Imatinib—Arthralgia—Methotrexate—hematologic cancer	2.38e-06	3.42e-05	CcSEcCtD
Imatinib—Chest pain—Methotrexate—hematologic cancer	2.38e-06	3.42e-05	CcSEcCtD
Imatinib—Myalgia—Methotrexate—hematologic cancer	2.38e-06	3.42e-05	CcSEcCtD
Imatinib—Decreased appetite—Prednisone—hematologic cancer	2.38e-06	3.41e-05	CcSEcCtD
Imatinib—Dysgeusia—Doxorubicin—hematologic cancer	2.37e-06	3.4e-05	CcSEcCtD
Imatinib—Rash—Prednisolone—hematologic cancer	2.37e-06	3.4e-05	CcSEcCtD
Imatinib—Dermatitis—Prednisolone—hematologic cancer	2.37e-06	3.4e-05	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	2.37e-06	3.39e-05	CcSEcCtD
Imatinib—Malaise—Epirubicin—hematologic cancer	2.36e-06	3.39e-05	CcSEcCtD
Imatinib—Fatigue—Prednisone—hematologic cancer	2.36e-06	3.38e-05	CcSEcCtD
Imatinib—Headache—Prednisolone—hematologic cancer	2.36e-06	3.38e-05	CcSEcCtD
Imatinib—Discomfort—Methotrexate—hematologic cancer	2.36e-06	3.37e-05	CcSEcCtD
Imatinib—Vertigo—Epirubicin—hematologic cancer	2.35e-06	3.37e-05	CcSEcCtD
Imatinib—Syncope—Epirubicin—hematologic cancer	2.35e-06	3.37e-05	CcSEcCtD
Imatinib—Leukopenia—Epirubicin—hematologic cancer	2.35e-06	3.36e-05	CcSEcCtD
Imatinib—Back pain—Doxorubicin—hematologic cancer	2.35e-06	3.36e-05	CcSEcCtD
Imatinib—Constipation—Prednisone—hematologic cancer	2.34e-06	3.35e-05	CcSEcCtD
Imatinib—Muscle spasms—Doxorubicin—hematologic cancer	2.33e-06	3.34e-05	CcSEcCtD
Imatinib—Palpitations—Epirubicin—hematologic cancer	2.32e-06	3.32e-05	CcSEcCtD
Imatinib—Confusional state—Methotrexate—hematologic cancer	2.3e-06	3.3e-05	CcSEcCtD
Imatinib—Loss of consciousness—Epirubicin—hematologic cancer	2.3e-06	3.3e-05	CcSEcCtD
Imatinib—Dizziness—Triamcinolone—hematologic cancer	2.29e-06	3.28e-05	CcSEcCtD
Imatinib—Cough—Epirubicin—hematologic cancer	2.29e-06	3.28e-05	CcSEcCtD
Imatinib—Anaphylactic shock—Methotrexate—hematologic cancer	2.29e-06	3.27e-05	CcSEcCtD
Imatinib—Vision blurred—Doxorubicin—hematologic cancer	2.29e-06	3.27e-05	CcSEcCtD
Imatinib—Convulsion—Epirubicin—hematologic cancer	2.27e-06	3.25e-05	CcSEcCtD
Imatinib—Infection—Methotrexate—hematologic cancer	2.27e-06	3.25e-05	CcSEcCtD
Imatinib—Nausea—Etoposide—hematologic cancer	2.27e-06	3.25e-05	CcSEcCtD
Imatinib—Hypertension—Epirubicin—hematologic cancer	2.26e-06	3.24e-05	CcSEcCtD
Imatinib—Feeling abnormal—Prednisone—hematologic cancer	2.25e-06	3.23e-05	CcSEcCtD
Imatinib—Asthenia—Betamethasone—hematologic cancer	2.25e-06	3.23e-05	CcSEcCtD
Imatinib—Asthenia—Dexamethasone—hematologic cancer	2.25e-06	3.23e-05	CcSEcCtD
Imatinib—Ill-defined disorder—Doxorubicin—hematologic cancer	2.25e-06	3.22e-05	CcSEcCtD
Imatinib—Nervous system disorder—Methotrexate—hematologic cancer	2.24e-06	3.21e-05	CcSEcCtD
Imatinib—Anaemia—Doxorubicin—hematologic cancer	2.24e-06	3.21e-05	CcSEcCtD
Imatinib—Thrombocytopenia—Methotrexate—hematologic cancer	2.24e-06	3.21e-05	CcSEcCtD
Imatinib—Gastrointestinal pain—Prednisone—hematologic cancer	2.24e-06	3.2e-05	CcSEcCtD
Imatinib—Nausea—Prednisolone—hematologic cancer	2.24e-06	3.2e-05	CcSEcCtD
Imatinib—Myalgia—Epirubicin—hematologic cancer	2.23e-06	3.2e-05	CcSEcCtD
Imatinib—Chest pain—Epirubicin—hematologic cancer	2.23e-06	3.2e-05	CcSEcCtD
Imatinib—Arthralgia—Epirubicin—hematologic cancer	2.23e-06	3.2e-05	CcSEcCtD
Imatinib—Anxiety—Epirubicin—hematologic cancer	2.22e-06	3.19e-05	CcSEcCtD
Imatinib—Pruritus—Dexamethasone—hematologic cancer	2.22e-06	3.18e-05	CcSEcCtD
Imatinib—Pruritus—Betamethasone—hematologic cancer	2.22e-06	3.18e-05	CcSEcCtD
Imatinib—Skin disorder—Methotrexate—hematologic cancer	2.22e-06	3.18e-05	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.22e-06	3.17e-05	CcSEcCtD
Imatinib—Hyperhidrosis—Methotrexate—hematologic cancer	2.21e-06	3.17e-05	CcSEcCtD
Imatinib—Discomfort—Epirubicin—hematologic cancer	2.2e-06	3.16e-05	CcSEcCtD
Imatinib—Vomiting—Triamcinolone—hematologic cancer	2.2e-06	3.15e-05	CcSEcCtD
Imatinib—Malaise—Doxorubicin—hematologic cancer	2.19e-06	3.13e-05	CcSEcCtD
Imatinib—Rash—Triamcinolone—hematologic cancer	2.18e-06	3.13e-05	CcSEcCtD
Imatinib—Dry mouth—Epirubicin—hematologic cancer	2.18e-06	3.13e-05	CcSEcCtD
Imatinib—Dermatitis—Triamcinolone—hematologic cancer	2.18e-06	3.12e-05	CcSEcCtD
Imatinib—Vertigo—Doxorubicin—hematologic cancer	2.18e-06	3.12e-05	CcSEcCtD
Imatinib—Anorexia—Methotrexate—hematologic cancer	2.18e-06	3.12e-05	CcSEcCtD
Imatinib—Syncope—Doxorubicin—hematologic cancer	2.17e-06	3.12e-05	CcSEcCtD
Imatinib—Urticaria—Prednisone—hematologic cancer	2.17e-06	3.11e-05	CcSEcCtD
Imatinib—Leukopenia—Doxorubicin—hematologic cancer	2.17e-06	3.11e-05	CcSEcCtD
Imatinib—Headache—Triamcinolone—hematologic cancer	2.17e-06	3.11e-05	CcSEcCtD
Imatinib—Abdominal pain—Prednisone—hematologic cancer	2.16e-06	3.1e-05	CcSEcCtD
Imatinib—Body temperature increased—Prednisone—hematologic cancer	2.16e-06	3.1e-05	CcSEcCtD
Imatinib—Confusional state—Epirubicin—hematologic cancer	2.16e-06	3.09e-05	CcSEcCtD
Imatinib—Diarrhoea—Betamethasone—hematologic cancer	2.15e-06	3.08e-05	CcSEcCtD
Imatinib—Diarrhoea—Dexamethasone—hematologic cancer	2.15e-06	3.08e-05	CcSEcCtD
Imatinib—Palpitations—Doxorubicin—hematologic cancer	2.14e-06	3.07e-05	CcSEcCtD
Imatinib—Oedema—Epirubicin—hematologic cancer	2.14e-06	3.06e-05	CcSEcCtD
Imatinib—Anaphylactic shock—Epirubicin—hematologic cancer	2.14e-06	3.06e-05	CcSEcCtD
Imatinib—Hypotension—Methotrexate—hematologic cancer	2.14e-06	3.06e-05	CcSEcCtD
Imatinib—Loss of consciousness—Doxorubicin—hematologic cancer	2.13e-06	3.05e-05	CcSEcCtD
Imatinib—Infection—Epirubicin—hematologic cancer	2.13e-06	3.04e-05	CcSEcCtD
Imatinib—Cough—Doxorubicin—hematologic cancer	2.12e-06	3.03e-05	CcSEcCtD
Imatinib—Shock—Epirubicin—hematologic cancer	2.1e-06	3.01e-05	CcSEcCtD
Imatinib—Convulsion—Doxorubicin—hematologic cancer	2.1e-06	3.01e-05	CcSEcCtD
Imatinib—Nervous system disorder—Epirubicin—hematologic cancer	2.1e-06	3.01e-05	CcSEcCtD
Imatinib—Thrombocytopenia—Epirubicin—hematologic cancer	2.09e-06	3e-05	CcSEcCtD
Imatinib—Hypertension—Doxorubicin—hematologic cancer	2.09e-06	3e-05	CcSEcCtD
Imatinib—Tachycardia—Epirubicin—hematologic cancer	2.09e-06	2.99e-05	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.08e-06	2.98e-05	CcSEcCtD
Imatinib—Skin disorder—Epirubicin—hematologic cancer	2.08e-06	2.98e-05	CcSEcCtD
Imatinib—Dizziness—Dexamethasone—hematologic cancer	2.08e-06	2.98e-05	CcSEcCtD
Imatinib—Dizziness—Betamethasone—hematologic cancer	2.08e-06	2.98e-05	CcSEcCtD
Imatinib—Hyperhidrosis—Epirubicin—hematologic cancer	2.07e-06	2.96e-05	CcSEcCtD
Imatinib—Insomnia—Methotrexate—hematologic cancer	2.07e-06	2.96e-05	CcSEcCtD
Imatinib—Arthralgia—Doxorubicin—hematologic cancer	2.06e-06	2.96e-05	CcSEcCtD
Imatinib—Chest pain—Doxorubicin—hematologic cancer	2.06e-06	2.96e-05	CcSEcCtD
Imatinib—Myalgia—Doxorubicin—hematologic cancer	2.06e-06	2.96e-05	CcSEcCtD
Imatinib—Anxiety—Doxorubicin—hematologic cancer	2.06e-06	2.95e-05	CcSEcCtD
Imatinib—Nausea—Triamcinolone—hematologic cancer	2.06e-06	2.95e-05	CcSEcCtD
Imatinib—Paraesthesia—Methotrexate—hematologic cancer	2.05e-06	2.94e-05	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.05e-06	2.94e-05	CcSEcCtD
Imatinib—Discomfort—Doxorubicin—hematologic cancer	2.04e-06	2.92e-05	CcSEcCtD
Imatinib—Anorexia—Epirubicin—hematologic cancer	2.04e-06	2.92e-05	CcSEcCtD
Imatinib—Dyspnoea—Methotrexate—hematologic cancer	2.04e-06	2.92e-05	CcSEcCtD
Imatinib—Somnolence—Methotrexate—hematologic cancer	2.03e-06	2.91e-05	CcSEcCtD
Imatinib—Dry mouth—Doxorubicin—hematologic cancer	2.02e-06	2.89e-05	CcSEcCtD
Imatinib—Hypersensitivity—Prednisone—hematologic cancer	2.01e-06	2.89e-05	CcSEcCtD
Imatinib—Dyspepsia—Methotrexate—hematologic cancer	2.01e-06	2.88e-05	CcSEcCtD
Imatinib—Hypotension—Epirubicin—hematologic cancer	2e-06	2.86e-05	CcSEcCtD
Imatinib—Vomiting—Betamethasone—hematologic cancer	2e-06	2.86e-05	CcSEcCtD
Imatinib—Vomiting—Dexamethasone—hematologic cancer	2e-06	2.86e-05	CcSEcCtD
Imatinib—Confusional state—Doxorubicin—hematologic cancer	2e-06	2.86e-05	CcSEcCtD
Imatinib—Decreased appetite—Methotrexate—hematologic cancer	1.99e-06	2.85e-05	CcSEcCtD
Imatinib—Rash—Dexamethasone—hematologic cancer	1.98e-06	2.84e-05	CcSEcCtD
Imatinib—Rash—Betamethasone—hematologic cancer	1.98e-06	2.84e-05	CcSEcCtD
Imatinib—Oedema—Doxorubicin—hematologic cancer	1.98e-06	2.84e-05	CcSEcCtD
Imatinib—Anaphylactic shock—Doxorubicin—hematologic cancer	1.98e-06	2.84e-05	CcSEcCtD
Imatinib—Dermatitis—Dexamethasone—hematologic cancer	1.98e-06	2.83e-05	CcSEcCtD
Imatinib—Dermatitis—Betamethasone—hematologic cancer	1.98e-06	2.83e-05	CcSEcCtD
Imatinib—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.97e-06	2.83e-05	CcSEcCtD
Imatinib—Fatigue—Methotrexate—hematologic cancer	1.97e-06	2.82e-05	CcSEcCtD
Imatinib—Headache—Dexamethasone—hematologic cancer	1.97e-06	2.82e-05	CcSEcCtD
Imatinib—Headache—Betamethasone—hematologic cancer	1.97e-06	2.82e-05	CcSEcCtD
Imatinib—Infection—Doxorubicin—hematologic cancer	1.97e-06	2.82e-05	CcSEcCtD
Imatinib—Asthenia—Prednisone—hematologic cancer	1.96e-06	2.81e-05	CcSEcCtD
Imatinib—Pain—Methotrexate—hematologic cancer	1.95e-06	2.8e-05	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.95e-06	2.79e-05	CcSEcCtD
Imatinib—Shock—Doxorubicin—hematologic cancer	1.95e-06	2.79e-05	CcSEcCtD
Imatinib—Nervous system disorder—Doxorubicin—hematologic cancer	1.94e-06	2.78e-05	CcSEcCtD
Imatinib—Thrombocytopenia—Doxorubicin—hematologic cancer	1.94e-06	2.78e-05	CcSEcCtD
Imatinib—Pruritus—Prednisone—hematologic cancer	1.93e-06	2.77e-05	CcSEcCtD
Imatinib—Insomnia—Epirubicin—hematologic cancer	1.93e-06	2.77e-05	CcSEcCtD
Imatinib—Tachycardia—Doxorubicin—hematologic cancer	1.93e-06	2.77e-05	CcSEcCtD
Imatinib—Skin disorder—Doxorubicin—hematologic cancer	1.92e-06	2.75e-05	CcSEcCtD
Imatinib—Paraesthesia—Epirubicin—hematologic cancer	1.92e-06	2.75e-05	CcSEcCtD
Imatinib—Hyperhidrosis—Doxorubicin—hematologic cancer	1.91e-06	2.74e-05	CcSEcCtD
Imatinib—Dyspnoea—Epirubicin—hematologic cancer	1.91e-06	2.73e-05	CcSEcCtD
Imatinib—Somnolence—Epirubicin—hematologic cancer	1.9e-06	2.72e-05	CcSEcCtD
Imatinib—Anorexia—Doxorubicin—hematologic cancer	1.89e-06	2.7e-05	CcSEcCtD
Imatinib—Feeling abnormal—Methotrexate—hematologic cancer	1.88e-06	2.7e-05	CcSEcCtD
Imatinib—Dyspepsia—Epirubicin—hematologic cancer	1.88e-06	2.7e-05	CcSEcCtD
Imatinib—Diarrhoea—Prednisone—hematologic cancer	1.87e-06	2.68e-05	CcSEcCtD
Imatinib—Gastrointestinal pain—Methotrexate—hematologic cancer	1.87e-06	2.68e-05	CcSEcCtD
Imatinib—Nausea—Betamethasone—hematologic cancer	1.87e-06	2.67e-05	CcSEcCtD
Imatinib—Nausea—Dexamethasone—hematologic cancer	1.87e-06	2.67e-05	CcSEcCtD
Imatinib—Decreased appetite—Epirubicin—hematologic cancer	1.86e-06	2.66e-05	CcSEcCtD
Imatinib—Hypotension—Doxorubicin—hematologic cancer	1.85e-06	2.65e-05	CcSEcCtD
Imatinib—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.85e-06	2.65e-05	CcSEcCtD
Imatinib—Fatigue—Epirubicin—hematologic cancer	1.84e-06	2.64e-05	CcSEcCtD
Imatinib—Constipation—Epirubicin—hematologic cancer	1.83e-06	2.62e-05	CcSEcCtD
Imatinib—Pain—Epirubicin—hematologic cancer	1.83e-06	2.62e-05	CcSEcCtD
Imatinib—Urticaria—Methotrexate—hematologic cancer	1.82e-06	2.6e-05	CcSEcCtD
Imatinib—Dizziness—Prednisone—hematologic cancer	1.81e-06	2.59e-05	CcSEcCtD
Imatinib—Abdominal pain—Methotrexate—hematologic cancer	1.81e-06	2.59e-05	CcSEcCtD
Imatinib—Body temperature increased—Methotrexate—hematologic cancer	1.81e-06	2.59e-05	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.8e-06	2.58e-05	CcSEcCtD
Imatinib—Insomnia—Doxorubicin—hematologic cancer	1.79e-06	2.56e-05	CcSEcCtD
Imatinib—Paraesthesia—Doxorubicin—hematologic cancer	1.78e-06	2.55e-05	CcSEcCtD
Imatinib—Dyspnoea—Doxorubicin—hematologic cancer	1.76e-06	2.53e-05	CcSEcCtD
Imatinib—Feeling abnormal—Epirubicin—hematologic cancer	1.76e-06	2.53e-05	CcSEcCtD
Imatinib—Somnolence—Doxorubicin—hematologic cancer	1.76e-06	2.52e-05	CcSEcCtD
Imatinib—Gastrointestinal pain—Epirubicin—hematologic cancer	1.75e-06	2.51e-05	CcSEcCtD
Imatinib—Dyspepsia—Doxorubicin—hematologic cancer	1.74e-06	2.5e-05	CcSEcCtD
Imatinib—Vomiting—Prednisone—hematologic cancer	1.74e-06	2.49e-05	CcSEcCtD
Imatinib—Rash—Prednisone—hematologic cancer	1.72e-06	2.47e-05	CcSEcCtD
Imatinib—Dermatitis—Prednisone—hematologic cancer	1.72e-06	2.47e-05	CcSEcCtD
Imatinib—Decreased appetite—Doxorubicin—hematologic cancer	1.72e-06	2.46e-05	CcSEcCtD
Imatinib—Headache—Prednisone—hematologic cancer	1.71e-06	2.45e-05	CcSEcCtD
Imatinib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.71e-06	2.45e-05	CcSEcCtD
Imatinib—Fatigue—Doxorubicin—hematologic cancer	1.71e-06	2.44e-05	CcSEcCtD
Imatinib—Urticaria—Epirubicin—hematologic cancer	1.7e-06	2.43e-05	CcSEcCtD
Imatinib—Constipation—Doxorubicin—hematologic cancer	1.69e-06	2.42e-05	CcSEcCtD
Imatinib—Pain—Doxorubicin—hematologic cancer	1.69e-06	2.42e-05	CcSEcCtD
Imatinib—Abdominal pain—Epirubicin—hematologic cancer	1.69e-06	2.42e-05	CcSEcCtD
Imatinib—Body temperature increased—Epirubicin—hematologic cancer	1.69e-06	2.42e-05	CcSEcCtD
Imatinib—Hypersensitivity—Methotrexate—hematologic cancer	1.68e-06	2.41e-05	CcSEcCtD
Imatinib—Asthenia—Methotrexate—hematologic cancer	1.64e-06	2.35e-05	CcSEcCtD
Imatinib—Feeling abnormal—Doxorubicin—hematologic cancer	1.63e-06	2.34e-05	CcSEcCtD
Imatinib—Nausea—Prednisone—hematologic cancer	1.62e-06	2.33e-05	CcSEcCtD
Imatinib—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.62e-06	2.32e-05	CcSEcCtD
Imatinib—Pruritus—Methotrexate—hematologic cancer	1.62e-06	2.32e-05	CcSEcCtD
Imatinib—Hypersensitivity—Epirubicin—hematologic cancer	1.58e-06	2.26e-05	CcSEcCtD
Imatinib—Urticaria—Doxorubicin—hematologic cancer	1.57e-06	2.25e-05	CcSEcCtD
Imatinib—Abdominal pain—Doxorubicin—hematologic cancer	1.56e-06	2.24e-05	CcSEcCtD
Imatinib—Body temperature increased—Doxorubicin—hematologic cancer	1.56e-06	2.24e-05	CcSEcCtD
Imatinib—Diarrhoea—Methotrexate—hematologic cancer	1.56e-06	2.24e-05	CcSEcCtD
Imatinib—Asthenia—Epirubicin—hematologic cancer	1.53e-06	2.2e-05	CcSEcCtD
Imatinib—Pruritus—Epirubicin—hematologic cancer	1.51e-06	2.17e-05	CcSEcCtD
Imatinib—Dizziness—Methotrexate—hematologic cancer	1.51e-06	2.17e-05	CcSEcCtD
Imatinib—Diarrhoea—Epirubicin—hematologic cancer	1.46e-06	2.1e-05	CcSEcCtD
Imatinib—Hypersensitivity—Doxorubicin—hematologic cancer	1.46e-06	2.09e-05	CcSEcCtD
Imatinib—Vomiting—Methotrexate—hematologic cancer	1.45e-06	2.08e-05	CcSEcCtD
Imatinib—Rash—Methotrexate—hematologic cancer	1.44e-06	2.06e-05	CcSEcCtD
Imatinib—Dermatitis—Methotrexate—hematologic cancer	1.44e-06	2.06e-05	CcSEcCtD
Imatinib—Headache—Methotrexate—hematologic cancer	1.43e-06	2.05e-05	CcSEcCtD
Imatinib—Asthenia—Doxorubicin—hematologic cancer	1.42e-06	2.03e-05	CcSEcCtD
Imatinib—Dizziness—Epirubicin—hematologic cancer	1.41e-06	2.03e-05	CcSEcCtD
Imatinib—Pruritus—Doxorubicin—hematologic cancer	1.4e-06	2.01e-05	CcSEcCtD
Imatinib—Vomiting—Epirubicin—hematologic cancer	1.36e-06	1.95e-05	CcSEcCtD
Imatinib—Nausea—Methotrexate—hematologic cancer	1.36e-06	1.94e-05	CcSEcCtD
Imatinib—Diarrhoea—Doxorubicin—hematologic cancer	1.35e-06	1.94e-05	CcSEcCtD
Imatinib—Rash—Epirubicin—hematologic cancer	1.35e-06	1.93e-05	CcSEcCtD
Imatinib—Dermatitis—Epirubicin—hematologic cancer	1.35e-06	1.93e-05	CcSEcCtD
Imatinib—Headache—Epirubicin—hematologic cancer	1.34e-06	1.92e-05	CcSEcCtD
Imatinib—Dizziness—Doxorubicin—hematologic cancer	1.31e-06	1.87e-05	CcSEcCtD
Imatinib—Nausea—Epirubicin—hematologic cancer	1.27e-06	1.82e-05	CcSEcCtD
Imatinib—Vomiting—Doxorubicin—hematologic cancer	1.26e-06	1.8e-05	CcSEcCtD
Imatinib—Rash—Doxorubicin—hematologic cancer	1.25e-06	1.79e-05	CcSEcCtD
Imatinib—Dermatitis—Doxorubicin—hematologic cancer	1.25e-06	1.79e-05	CcSEcCtD
Imatinib—Headache—Doxorubicin—hematologic cancer	1.24e-06	1.78e-05	CcSEcCtD
Imatinib—Nausea—Doxorubicin—hematologic cancer	1.18e-06	1.68e-05	CcSEcCtD
Imatinib—NTRK1—Signaling Pathways—HRAS—hematologic cancer	2.24e-07	4.96e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.24e-07	4.96e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—MTR—hematologic cancer	2.23e-07	4.94e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ABCG2—hematologic cancer	2.23e-07	4.94e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTP1—hematologic cancer	2.23e-07	4.94e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCND1—hematologic cancer	2.22e-07	4.92e-06	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HRAS—hematologic cancer	2.22e-07	4.92e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—JUN—hematologic cancer	2.22e-07	4.91e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CB—hematologic cancer	2.22e-07	4.91e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—MTHFR—hematologic cancer	2.21e-07	4.9e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SRC—hematologic cancer	2.21e-07	4.89e-06	CbGpPWpGaD
Imatinib—LCK—Disease—STAT3—hematologic cancer	2.2e-07	4.87e-06	CbGpPWpGaD
Imatinib—LCK—Disease—NRAS—hematologic cancer	2.19e-07	4.86e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—NCOR1—hematologic cancer	2.19e-07	4.86e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GSTM1—hematologic cancer	2.19e-07	4.86e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—FGF2—hematologic cancer	2.19e-07	4.85e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ENO2—hematologic cancer	2.19e-07	4.85e-06	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HRAS—hematologic cancer	2.17e-07	4.8e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYCS—hematologic cancer	2.16e-07	4.79e-06	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PIK3CA—hematologic cancer	2.16e-07	4.79e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3R1—hematologic cancer	2.16e-07	4.78e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CG—hematologic cancer	2.16e-07	4.78e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.16e-07	4.78e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—hematologic cancer	2.15e-07	4.76e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CDKN1A—hematologic cancer	2.15e-07	4.76e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MAPK3—hematologic cancer	2.15e-07	4.76e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	2.15e-07	4.76e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PTEN—hematologic cancer	2.15e-07	4.75e-06	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL6—hematologic cancer	2.15e-07	4.75e-06	CbGpPWpGaD
Imatinib—ALB—Hemostasis—PIK3CA—hematologic cancer	2.14e-07	4.74e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—STAT3—hematologic cancer	2.13e-07	4.72e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CB—hematologic cancer	2.13e-07	4.72e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ABCB1—hematologic cancer	2.13e-07	4.72e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—NRAS—hematologic cancer	2.13e-07	4.71e-06	CbGpPWpGaD
Imatinib—PDGFRA—Disease—IL6—hematologic cancer	2.13e-07	4.71e-06	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—AKT1—hematologic cancer	2.12e-07	4.7e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTT1—hematologic cancer	2.12e-07	4.7e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ABCB1—hematologic cancer	2.11e-07	4.68e-06	CbGpPWpGaD
Imatinib—ABL1—Immune System—HRAS—hematologic cancer	2.11e-07	4.68e-06	CbGpPWpGaD
Imatinib—LCK—Disease—MAPK3—hematologic cancer	2.1e-07	4.65e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MAPK8—hematologic cancer	2.1e-07	4.65e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—JAK2—hematologic cancer	2.1e-07	4.65e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MYC—hematologic cancer	2.09e-07	4.63e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TGFB1—hematologic cancer	2.09e-07	4.62e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SDC1—hematologic cancer	2.07e-07	4.59e-06	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL6—hematologic cancer	2.07e-07	4.59e-06	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—hematologic cancer	2.07e-07	4.59e-06	CbGpPWpGaD
Imatinib—KIT—Disease—AKT1—hematologic cancer	2.07e-07	4.59e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTM1—hematologic cancer	2.07e-07	4.58e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—NCOR1—hematologic cancer	2.07e-07	4.58e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTM1—hematologic cancer	2.05e-07	4.54e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—NCOR1—hematologic cancer	2.05e-07	4.54e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MDM2—hematologic cancer	2.05e-07	4.54e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EP300—hematologic cancer	2.05e-07	4.53e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—KRAS—hematologic cancer	2.05e-07	4.53e-06	CbGpPWpGaD
Imatinib—LCK—Disease—MYC—hematologic cancer	2.04e-07	4.53e-06	CbGpPWpGaD
Imatinib—LCK—Disease—TGFB1—hematologic cancer	2.04e-07	4.51e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MAPK3—hematologic cancer	2.04e-07	4.51e-06	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL6—hematologic cancer	2.02e-07	4.47e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CREBBP—hematologic cancer	2e-07	4.43e-06	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HRAS—hematologic cancer	2e-07	4.43e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTEN—hematologic cancer	2e-07	4.42e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MTOR—hematologic cancer	1.99e-07	4.41e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CB—hematologic cancer	1.99e-07	4.41e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SRC—hematologic cancer	1.99e-07	4.41e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—MTHFR—hematologic cancer	1.99e-07	4.4e-06	CbGpPWpGaD
Imatinib—ALB—Hemostasis—HRAS—hematologic cancer	1.98e-07	4.39e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MYC—hematologic cancer	1.98e-07	4.38e-06	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AKT1—hematologic cancer	1.98e-07	4.38e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTEN—hematologic cancer	1.98e-07	4.38e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TGFB1—hematologic cancer	1.98e-07	4.37e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTEN—hematologic cancer	1.97e-07	4.37e-06	CbGpPWpGaD
Imatinib—PDGFRA—Disease—AKT1—hematologic cancer	1.96e-07	4.34e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.95e-07	4.32e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—MTHFR—hematologic cancer	1.94e-07	4.29e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—hematologic cancer	1.94e-07	4.29e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.93e-07	4.28e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—KRAS—hematologic cancer	1.93e-07	4.28e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—STAT3—hematologic cancer	1.92e-07	4.25e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTEN—hematologic cancer	1.92e-07	4.24e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NRAS—hematologic cancer	1.91e-07	4.24e-06	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IL6—hematologic cancer	1.91e-07	4.24e-06	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—AKT1—hematologic cancer	1.91e-07	4.24e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTP1—hematologic cancer	1.91e-07	4.22e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—EP300—hematologic cancer	1.9e-07	4.21e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CD—hematologic cancer	1.9e-07	4.2e-06	CbGpPWpGaD
Imatinib—LCK—Disease—KRAS—hematologic cancer	1.89e-07	4.18e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—EP300—hematologic cancer	1.89e-07	4.18e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—EP300—hematologic cancer	1.88e-07	4.17e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—PIK3CA—hematologic cancer	1.88e-07	4.16e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ALB—hematologic cancer	1.87e-07	4.15e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CDKN1B—hematologic cancer	1.87e-07	4.14e-06	CbGpPWpGaD
Imatinib—ABL1—Immune System—AKT1—hematologic cancer	1.86e-07	4.13e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CG—hematologic cancer	1.86e-07	4.12e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.84e-07	4.08e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTEN—hematologic cancer	1.84e-07	4.08e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MAPK3—hematologic cancer	1.83e-07	4.06e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CASP3—hematologic cancer	1.83e-07	4.06e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL2—hematologic cancer	1.83e-07	4.05e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KRAS—hematologic cancer	1.83e-07	4.05e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—EP300—hematologic cancer	1.83e-07	4.05e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—MTHFR—hematologic cancer	1.83e-07	4.05e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—MTHFR—hematologic cancer	1.81e-07	4.01e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ABCB1—hematologic cancer	1.8e-07	4e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3R1—hematologic cancer	1.79e-07	3.97e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCND1—hematologic cancer	1.78e-07	3.95e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MYC—hematologic cancer	1.78e-07	3.95e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—JUN—hematologic cancer	1.78e-07	3.94e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TGFB1—hematologic cancer	1.78e-07	3.94e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PIK3CA—hematologic cancer	1.78e-07	3.93e-06	CbGpPWpGaD
Imatinib—PDGFRB—Disease—AKT1—hematologic cancer	1.77e-07	3.91e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NQO1—hematologic cancer	1.76e-07	3.91e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CD44—hematologic cancer	1.76e-07	3.91e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—EP300—hematologic cancer	1.76e-07	3.89e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—NCOR1—hematologic cancer	1.75e-07	3.88e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTM1—hematologic cancer	1.75e-07	3.88e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.75e-07	3.88e-06	CbGpPWpGaD
Imatinib—ALB—Hemostasis—AKT1—hematologic cancer	1.75e-07	3.88e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—HRAS—hematologic cancer	1.74e-07	3.85e-06	CbGpPWpGaD
Imatinib—LCK—Disease—PIK3CA—hematologic cancer	1.74e-07	3.84e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CDKN1A—hematologic cancer	1.73e-07	3.82e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—CREBBP—hematologic cancer	1.72e-07	3.82e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PTEN—hematologic cancer	1.72e-07	3.81e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—hematologic cancer	1.72e-07	3.8e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAPK8—hematologic cancer	1.68e-07	3.73e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PIK3CA—hematologic cancer	1.68e-07	3.72e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CG—hematologic cancer	1.67e-07	3.7e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYCS—hematologic cancer	1.67e-07	3.7e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—IL6—hematologic cancer	1.66e-07	3.68e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.66e-07	3.67e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CB—hematologic cancer	1.65e-07	3.66e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KRAS—hematologic cancer	1.65e-07	3.65e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—HRAS—hematologic cancer	1.64e-07	3.64e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EP300—hematologic cancer	1.64e-07	3.64e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CD—hematologic cancer	1.63e-07	3.62e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.63e-07	3.61e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—hematologic cancer	1.63e-07	3.6e-06	CbGpPWpGaD
Imatinib—LCK—Disease—HRAS—hematologic cancer	1.61e-07	3.55e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SRC—hematologic cancer	1.6e-07	3.54e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.6e-07	3.54e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL6—hematologic cancer	1.57e-07	3.48e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—hematologic cancer	1.56e-07	3.44e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—HRAS—hematologic cancer	1.55e-07	3.44e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—MTHFR—hematologic cancer	1.55e-07	3.43e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CREBBP—hematologic cancer	1.55e-07	3.43e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3R1—hematologic cancer	1.54e-07	3.42e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—STAT3—hematologic cancer	1.54e-07	3.41e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NRAS—hematologic cancer	1.54e-07	3.4e-06	CbGpPWpGaD
Imatinib—LCK—Disease—IL6—hematologic cancer	1.54e-07	3.4e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.54e-07	3.4e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—AKT1—hematologic cancer	1.54e-07	3.4e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CG—hematologic cancer	1.52e-07	3.37e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PIK3CA—hematologic cancer	1.51e-07	3.35e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CREBBP—hematologic cancer	1.51e-07	3.34e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL6—hematologic cancer	1.49e-07	3.3e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAPK3—hematologic cancer	1.47e-07	3.26e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.47e-07	3.26e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CD—hematologic cancer	1.47e-07	3.25e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—hematologic cancer	1.46e-07	3.24e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AKT1—hematologic cancer	1.45e-07	3.21e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ALB—hematologic cancer	1.45e-07	3.21e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CD—hematologic cancer	1.43e-07	3.17e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MYC—hematologic cancer	1.43e-07	3.17e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTEN—hematologic cancer	1.43e-07	3.17e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TGFB1—hematologic cancer	1.43e-07	3.16e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CB—hematologic cancer	1.42e-07	3.16e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CREBBP—hematologic cancer	1.42e-07	3.15e-06	CbGpPWpGaD
Imatinib—LCK—Disease—AKT1—hematologic cancer	1.42e-07	3.14e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ALB—hematologic cancer	1.41e-07	3.13e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CREBBP—hematologic cancer	1.41e-07	3.12e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PIK3CA—hematologic cancer	1.41e-07	3.12e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HRAS—hematologic cancer	1.4e-07	3.1e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PIK3CA—hematologic cancer	1.4e-07	3.09e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PIK3CA—hematologic cancer	1.39e-07	3.08e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.39e-07	3.08e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3R1—hematologic cancer	1.39e-07	3.07e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AKT1—hematologic cancer	1.37e-07	3.04e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.36e-07	3.02e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—EP300—hematologic cancer	1.36e-07	3.02e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.35e-07	2.99e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CA—hematologic cancer	1.35e-07	2.99e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.35e-07	2.99e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.35e-07	2.99e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.35e-07	2.99e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL6—hematologic cancer	1.34e-07	2.97e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CD—hematologic cancer	1.34e-07	2.96e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ALB—hematologic cancer	1.33e-07	2.95e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KRAS—hematologic cancer	1.32e-07	2.93e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ALB—hematologic cancer	1.32e-07	2.92e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CG—hematologic cancer	1.3e-07	2.88e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CA—hematologic cancer	1.3e-07	2.88e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CB—hematologic cancer	1.28e-07	2.83e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.27e-07	2.82e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3R1—hematologic cancer	1.26e-07	2.8e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.25e-07	2.76e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AKT1—hematologic cancer	1.24e-07	2.74e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTEN—hematologic cancer	1.23e-07	2.73e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CA—hematologic cancer	1.22e-07	2.69e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.21e-07	2.67e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.19e-07	2.65e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.18e-07	2.61e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—hematologic cancer	1.18e-07	2.6e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—EP300—hematologic cancer	1.17e-07	2.6e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CB—hematologic cancer	1.17e-07	2.58e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—AKT1—hematologic cancer	1.15e-07	2.55e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.14e-07	2.53e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—AKT1—hematologic cancer	1.14e-07	2.52e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—AKT1—hematologic cancer	1.14e-07	2.52e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ALB—hematologic cancer	1.13e-07	2.5e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HRAS—hematologic cancer	1.12e-07	2.49e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTEN—hematologic cancer	1.11e-07	2.45e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—AKT1—hematologic cancer	1.1e-07	2.45e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.08e-07	2.39e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTEN—hematologic cancer	1.08e-07	2.39e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6—hematologic cancer	1.08e-07	2.38e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—AKT1—hematologic cancer	1.06e-07	2.35e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—EP300—hematologic cancer	1.05e-07	2.33e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—EP300—hematologic cancer	1.03e-07	2.28e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTEN—hematologic cancer	1.02e-07	2.25e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CA—hematologic cancer	1.01e-07	2.23e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTEN—hematologic cancer	1.01e-07	2.23e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1e-07	2.22e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CB—hematologic cancer	9.97e-08	2.21e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AKT1—hematologic cancer	9.93e-08	2.2e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—EP300—hematologic cancer	9.7e-08	2.15e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—EP300—hematologic cancer	9.61e-08	2.13e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CREBBP—hematologic cancer	9.31e-08	2.06e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CD—hematologic cancer	8.83e-08	1.95e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ALB—hematologic cancer	8.71e-08	1.93e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CA—hematologic cancer	8.69e-08	1.92e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTEN—hematologic cancer	8.61e-08	1.91e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3R1—hematologic cancer	8.33e-08	1.85e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AKT1—hematologic cancer	8.24e-08	1.82e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—EP300—hematologic cancer	8.21e-08	1.82e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CA—hematologic cancer	7.8e-08	1.73e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CB—hematologic cancer	7.69e-08	1.7e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CA—hematologic cancer	7.61e-08	1.69e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CA—hematologic cancer	7.17e-08	1.59e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CA—hematologic cancer	7.11e-08	1.57e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—AKT1—hematologic cancer	7.1e-08	1.57e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTEN—hematologic cancer	6.65e-08	1.47e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AKT1—hematologic cancer	6.37e-08	1.41e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—EP300—hematologic cancer	6.34e-08	1.4e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AKT1—hematologic cancer	6.22e-08	1.38e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CA—hematologic cancer	6.08e-08	1.35e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AKT1—hematologic cancer	5.86e-08	1.3e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AKT1—hematologic cancer	5.81e-08	1.29e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AKT1—hematologic cancer	4.96e-08	1.1e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CA—hematologic cancer	4.69e-08	1.04e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKT1—hematologic cancer	3.83e-08	8.48e-07	CbGpPWpGaD
